Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
China study indicates bias against men who have sex with men spurs migration, potential spread of HIV, stalls services, responses
Study highlights role of dating website in filling gaps The quest is for anonymity, but the result is closer to invisibililty. While the numbers of men […]
Health workers face tuberculosis risks up to three times those of general population, while infection control, worker protections lag
The devastation of the last two years of the Ebola crisis in West Africa was made all the more daunting by a predictable aspect of its […]
In 2003, a study published in the journal Nature told of a vaccine candidate that showed promise against Ebola when tried on monkeys. With funding or financial incentives, […]
Health and human rights concerns “considered” but not confronted in UNGASS drug policy document To leaders of global infectious disease responses and advocates of human rights, […]